Cargando…

Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis

This post hoc analysis examined SCORing Atopic Dermatitis (SCORAD) outcomes in 471 paediatric patients (children age 6–<12 years, n = 304; adolescents age 12–<18 years, n = 167) with atopic dermatitis treated with dupilumab, ± topical corticosteroids, in two 16-week phase 3 randomized controll...

Descripción completa

Detalles Bibliográficos
Autores principales:	WOLLENBERG, Andreas, MARCOUX, Danielle, SILVERBERG, Jonathan I., AOKI, Valeria, BASELGA, Eulalia, ZHANG, Haixin, LEVIT, Noah A., TAIEB, Alain, ROSSI, Ana B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society for Publication of Acta Dermato-Venereologica 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631288/ https://www.ncbi.nlm.nih.gov/pubmed/35393631 http://dx.doi.org/10.2340/actadv.v102.854

Ejemplares similares

Dupilumab for atopic dermatitis
Publicado: (2019)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)

Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
por: SILVERBERG, Jonathan I., et al.
Publicado: (2021)

Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
por: de Bruin-Weller, Marjolein, et al.
Publicado: (2021)

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2022)

Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use
por: DELEURAN, Mette, et al.
Publicado: (2021)

A case report of uveitis secondary to dupilumab treatment for atopic dermatitis
por: Ayasse, Marissa, et al.
Publicado: (2020)

Alopecia areata after dupilumab for atopic dermatitis
por: Mitchell, Krystal, et al.
Publicado: (2018)

Conjunctivitis in patients with atopic dermatitis treated with dupilumab
por: Ferreira, Sandra, et al.
Publicado: (2020)

Onychodystrophy associated with dupilumab therapy for atopic dermatitis
por: Zubek, Amanda E., et al.
Publicado: (2020)

Practical Management of Patients with Atopic Dermatitis on Dupilumab
por: Papp, Kim A., et al.
Publicado: (2021)

The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis
por: Kamal, Mohamed A., et al.
Publicado: (2021)

Improvement of atopic dermatitis and alopecia universalis with dupilumab
por: Alotaibi, Lama, et al.
Publicado: (2021)

Dupilumab in the Treatment of Cheilitis in Atopic Dermatitis Patients
por: Shan, Jinpeng, et al.
Publicado: (2022)

Immune Thrombocytopenic Purpura in a Patient with Atopic Dermatitis Treated with Dupilumab
por: FREY, Surina, et al.
Publicado: (2021)

Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy
por: Peterson, Danielle M., et al.
Publicado: (2021)

Difficult to control atopic dermatitis
por: Darsow, Ulf, et al.
Publicado: (2013)

The evaluation of dupilumab treatment response in atopic dermatitis patients
por: Askin, Ozge, et al.
Publicado: (2020)

Dupilumab for the treatment of alopecia areata in children with atopic dermatitis
por: Cho, Sung Kyung, et al.
Publicado: (2021)

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
por: Beck, Lisa A., et al.
Publicado: (2022)

Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis
por: Maudinet, Adrien, et al.
Publicado: (2019)

Effectiveness of Dupilumab in the treatment of both atopic dermatitis and alopecia universalis
por: Call, John E., et al.
Publicado: (2020)

Dupilumab-induced phenotype switching from atopic dermatitis to psoriasis
por: Varma, Aakaash, et al.
Publicado: (2020)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)

Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis
por: Giavina-Bianchi, Mara, et al.
Publicado: (2021)

Long-term Remission of Atopic Dermatitis after Discontinuation of Dupilumab
por: MIYAMOTO, Shoko, et al.
Publicado: (2022)

Pharmacokinetics, pharmacodynamics, and exposure–efficacy of dupilumab in adults with atopic dermatitis
por: Kamal, Mohamed A., et al.
Publicado: (2022)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
por: Esposito, Maria, et al.
Publicado: (2022)

Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis
por: Ferrari, Marco, et al.
Publicado: (2023)

The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis
por: Spekhorst, Lotte S., et al.
Publicado: (2023)

Effectiveness of dupilumab for chronic prurigo in elderly patients with atopic dermatitis()
por: Mitsuyama, Shinji, et al.
Publicado: (2023)

Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer
por: Tanczosova, Milena, et al.
Publicado: (2023)

Asthma improvement in patients treated with dupilumab for severe atopic dermatitis
por: Dubini, Marco, et al.
Publicado: (2023)

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
por: Eichenfield, Lawrence F., et al.
Publicado: (2019)

Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis
por: Yosipovitch, Gil, et al.
Publicado: (2021)

No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion
por: Thyssen, J.P., et al.
Publicado: (2019)

Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Nomenclature and clinical phenotypes of atopic dermatitis
por: Girolomoni, Giampiero, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p29h8s8l6fdg38gadfu11jgg9m